Fantastisk nyhed hørt på BBC. Desværre går der jo nok mindst 10 år før, man får diverse godkendelser på plads, men alligevel en fantastisk nyhed.
https://www.bbc.com/news/health-51182451
https://www.bbc.com/news/health-51182451
20/1 2020 21:45 tommycarstensen 2
81003 Thorkild01 Spaendende. Tak.
"Why is this significant?
T-cell cancer therapies already exist and the development of cancer immunotherapy has been one of the most exciting advances in the field.
The most famous example is CAR-T - a living drug made by genetically engineering a patient's T-cells to seek out and destroy cancer.
CAR-T can have dramatic results that transform some patients from being terminally ill to being in complete remission.
However, the approach is highly specific and works in only a limited number of cancers where there is a clear target to train the T-cells to spot.
And it has struggled to have any success in "solid cancers" - those that form tumours rather than blood cancers such as leukaemia.
The researchers say their T-cell receptor could lead to a "universal" cancer treatment."
To eksisterende terapier, der begge koster i omegnen af en halv million dollar, er:
Yescarta® fra Kite Pharma (nu Gilead Sciences)
https://en.wikipedia.org/wiki/Axicabtagene_ciloleucel
https://www.yescarta.com/
Kymriah® fra Novartis
https://en.wikipedia.org/wiki/Tisagenlecleucel
https://www.kymriah.com/
"Why is this significant?
T-cell cancer therapies already exist and the development of cancer immunotherapy has been one of the most exciting advances in the field.
The most famous example is CAR-T - a living drug made by genetically engineering a patient's T-cells to seek out and destroy cancer.
CAR-T can have dramatic results that transform some patients from being terminally ill to being in complete remission.
However, the approach is highly specific and works in only a limited number of cancers where there is a clear target to train the T-cells to spot.
And it has struggled to have any success in "solid cancers" - those that form tumours rather than blood cancers such as leukaemia.
The researchers say their T-cell receptor could lead to a "universal" cancer treatment."
To eksisterende terapier, der begge koster i omegnen af en halv million dollar, er:
Yescarta® fra Kite Pharma (nu Gilead Sciences)
https://en.wikipedia.org/wiki/Axicabtagene_ciloleucel
https://www.yescarta.com/
Kymriah® fra Novartis
https://en.wikipedia.org/wiki/Tisagenlecleucel
https://www.kymriah.com/
